Imagine discovering that surviving one cancer might set the stage for another lurking in the shadows—this is the startling reality facing women with ovarian or colorectal cancer, according to a groundbreaking review that urges us to rethink surveillance strategies.
Delving deeper into this unsettling connection, a comprehensive analysis reveals that women battling ovarian or colorectal cancer are at an elevated risk of encountering the other type, underscoring the critical need for vigilant monitoring.
In a detailed examination published in the Korean Journal of Clinical Oncology, researchers uncovered what appears to be a two-way street of risk between ovarian cancer—often a stealthy threat to women's health—and colorectal cancer, which affects the colon or rectum. This isn't just coincidence; it points to potential shared genetic underpinnings that could make some individuals more susceptible to both diseases.
But here's where it gets controversial: While we've long treated these cancers as separate entities, this review challenges that by suggesting they're intertwined in ways we haven't fully explored. Ovarian and colorectal cancers rank high among the world's most common malignancies, creating significant challenges for public health, especially for women. Despite the usual silos in cancer research, growing evidence hints at a link, possibly through common genetic factors that increase vulnerability to multiple cancers. For beginners, think of it like this: Just as certain family histories might predispose someone to heart disease and diabetes, shared genes could be the hidden thread connecting ovarian and colorectal tumors.
Yet, the data has been patchy. We know little about the odds of colorectal cancer in ovarian cancer survivors, or vice versa. To fill this void, the team performed a systematic review and meta-analysis, even zooming in on borderline ovarian tumors (BOTs)—those tricky growths that aren't fully cancerous but could be precursors—and their subtypes, like serous and mucinous variants.
To measure these risks, they relied on standardized incidence ratios (SIRs), a statistical tool that compares the actual cancer rates in these patients to what we'd expect in the general population. It's like checking if your town's crime rate spikes after a certain event—higher SIRs signal an increased danger. This method helped paint a clearer picture of bidirectional risks.
Their search, conducted on September 27, 2024, combed through databases like Scopus, Web of Science, PubMed, and Google Scholar. They sifted through titles and abstracts first, then dove into full texts, narrowing down from thousands of studies—2,544 from Web of Science, 2,869 from Scopus, and 1,137 from PubMed—to just 20 for the final cut. These were all retrospective cohort studies drawn from national registries, spanning from 1987 to 2023, offering a robust historical perspective.
And this is the part most people miss: The findings don't just confirm higher risks—they illuminate how specific cancer types and treatments might amplify the danger.
Women with ovarian cancer showed a notably higher chance of developing colorectal cancer overall (SIR of 1.69, with a 95% confidence interval of 1.39-1.98). This included bumps in colon cancer risk (SIR 1.57, CI 1.14-1.99) and rectal cancer (SIR 1.58, CI 1.38-1.78). For those with BOTs, the colorectal risk was elevated at 1.27 (CI 0.99-1.55), particularly in serous subtypes (SIR 1.38, CI 1.09-1.67). This suggests that the biology of certain ovarian tumors might forge a stronger link to colorectal issues, begging for more research into how these cancers interact at a cellular level.
Flipping the script, women with colorectal cancer faced an increased ovarian cancer risk (SIR 1.48, CI 1.17-1.79). Colon cancer patients saw a sharper rise (SIR 1.64, CI 1.25-2.03), while rectal cancer cases had a slight dip (SIR 0.88, CI 0.77-0.99). Altogether, this reinforces a bidirectional pattern, where one cancer could pave the way for the other.
Treatments play a starring role too. Chemotherapy, for instance, seemed to boost the chances of both colon and rectal cancers down the line, possibly due to how these drugs affect the body long-term. Pairing radiotherapy with chemotherapy heightened rectal cancer risks even more. To illustrate, imagine chemotherapy as a powerful medicine that battles the primary cancer but might inadvertently weaken defenses against future threats, like leaving a garden vulnerable to new weeds after pulling out the old ones.
“These results stress the need to keep a close eye on women receiving chemo or combo therapies for ovarian cancer, watching for signs of colorectal issues,” the researchers emphasized.
Here's a controversial twist: Could our aggressive treatments be inadvertently fueling secondary cancers, or is it all about genetics? This opens a debate—do we need to rethink treatment plans to minimize these risks, or focus more on genetic screening upfront?
Looking ahead, the authors acknowledged drawbacks in their work, like relying solely on retrospective studies, which can't prove cause-and-effect, and overlooking variables such as lifestyle choices, family backgrounds, or genetic profiles that might influence outcomes. Still, they're optimistic about the insights gained and call for deeper dives.
“Advanced genetic research is essential to unravel the molecular mysteries behind this,” they note. “Plus, our findings highlight why proactive surveillance and early detection are vital for women who've faced ovarian or colorectal cancer.” For clarity, surveillance might involve regular check-ups, like colonoscopies or blood tests, to catch potential problems early—think of it as routine car maintenance to prevent breakdowns.
References
Ramadan H. The relationship between ovarian and colorectal cancers: a systematic review and meta-analysis. Korean J Clin Oncol. Published online December 19, 2025. doi:10.14216/kjco.25355
Shah S, Cheung A, Kutka M, Sheriff M, Boussios S. Epithelial ovarian cancer: providing evidence of predisposition genes. Int J Environ Res Public Health. 2022;19(13):8113. doi:10.3390/ijerph19138113
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
What do you think? Does this bidirectional risk change how we approach cancer prevention, or is it just another layer in the complex puzzle of oncology? Do you agree that treatments might be contributing to secondary cancers, or should we prioritize genetic factors instead? Share your thoughts and opinions in the comments—let's discuss!
